$6.69
0.07% yesterday
Nasdaq, Jun 24, 07:19 pm CET
ISIN
US6412881053
Symbol
NPCE

NeuroPace Inc Share price

$6.69
-0.84 11.16% 1M
-2.38 26.24% 6M
-3.62 35.11% YTD
+2.18 48.34% 1Y
-17.67 72.54% 3Y
-10.31 60.65% 5Y
-10.31 60.65% 10Y
Nasdaq, Closing price Mon, Jun 24 2024
ISIN
US6412881053
Symbol
NPCE
Sector

Key figures

Market capitalization $192.46m
Enterprise Value $206.60m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.99
P/S ratio (TTM) P/S ratio 2.79
P/B ratio (TTM) P/B ratio 13.40
Sales growth (TTM) Sales growth 42.07%
Turnover (TTM) Turnover $69.07m
EBIT (operating result TTM) EBIT $-26.40m
Free cash flow (TTM) Free cash flow $-17.68m
Cash position $58.95m
EPS (TTM) EPS $-1.18
P/E ratio expected negative
P/S ratio expected 2.54
EV/Sales expected 2.72
Short interest 0.92%
Show more

Is NeuroPace Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,950 shares worldwide.

NeuroPace Inc Share analysis

Unlock scores for free

Analyst opinions

7 Analysts have issued a NeuroPace Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst opinions

7 Analysts have issued a NeuroPace Inc forecast:

Buy
86%
Hold
14%

Financial data from NeuroPace Inc

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
69 69
42% 42%
100%
- Direct costs 18 18
28% 28%
26%
51 51
48% 48%
74%
- Selling and administrative expenses 55 55
10% 10%
79%
- Research and development costs 21 21
2% 2%
31%
-25 -25
33% 33%
-36%
- Depreciation and amortization 1.63 1.63
38% 38%
2%
EBIT (operating result) EBIT -26 -26
33% 33%
-38%
Net profit -32 -32
32% 32%
-46%

Figures in millions USD.

Don't miss a thing! We will send you all news about the NeuroPace Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

NeuroPace Inc Share News

Neutral
Seeking Alpha
about one month ago
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Mike Kratky - Leerink Partners Frank Takkinen - Lake Street Capital Markets Vik Chopra - Wells Fargo Ross Osborn - Cantor Fitzgeral...
Neutral
GlobeNewsWire
about 2 months ago
-- Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 -- -- Extended the maturity date of the Company's term loan by one year to September 30, 2026 --
Neutral
GlobeNewsWire
2 months ago
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m...
More NeuroPace Inc News

Company profile

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.

Head office United States
CEO Joel Becker
Employees 171
Founded 1997
Website www.neuropace.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now